Series C funding round for Prellis Biologics raising $35M in August 2022
Series C funding round for Prellis Biologics raising $35M in August 2022
| Investor | Firm Type | Partner |
|---|
Celesta CapitalLEAD | Venture Capital | — |
Avidity PartnersLEAD | Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Angel | Sam Altman |
| Angel | Louis Beryl |
| Angel | Paul Graham |
| Angel | Martin Añazco |
| Angel | Michael Moritz |
| Angel | Matt Bellamy |
| Angel | Mattia Astori |
| Angel | Sahin Boydas |
| Angel | Alexander Gerko |
| Angel | Sue Xu |
This company has completed 7 funding rounds. Current round is highlighted.
Total Raised
$83.1M
Top Valuation
-
Prellis Biologics raised $35M in a Series C round.
The round was announced on 08/01/22.
The round was led by Lei Meng, Michael Marks.